论文部分内容阅读
福州神州医药技术开发有限公司研制开发的新一代纯中药抗癌制剂慈丹胶囊,经卫生部指定在北京中医药大学东直门医院等6家大医院进行大样本临床试验。该药适用于原发性肝癌、肺癌、胃癌、食道癌、乳腺癌、结肠癌等多种恶性肿瘤的治疗,其中单纯用慈丹胶囊治疗肝癌,其稳定以上率可达72.8％;配合导管化疗,可明显提高瘤体缓解率,其有效率为52％。较单纯做导管化疗(有效率29％)为优。同时可减轻疼痛及放化疗引起的毒副作用。
Fudan Shenzhou Medical Technology Development Co., Ltd. researched and developed a new generation of pure Chinese medicine anticancer preparation Cidan capsules, which was designated by the Ministry of Health to conduct large-scale clinical trials in 6 major hospitals, including Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. The drug is suitable for the treatment of primary liver cancer, lung cancer, gastric cancer, esophageal cancer, breast cancer, colon cancer, and other malignant tumors, of which the use of Cidan Capsule alone for the treatment of liver cancer, the stability of the above rate up to 72.8%; with catheter chemotherapy , Can significantly improve the tumor remission rate, the effective rate is 52%. It is superior to catheter chemotherapy alone (29% efficiency). At the same time can reduce the pain and the side effects caused by radiotherapy and chemotherapy.